HomeoTherapy

HomeoTherapy was a South Korea-based private biotech company focused on mesenchymal stem cell therapeutics and regenerative medicine. The company sponsored a Phase 1 clinical study of Homeo-GH, an allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for acute and chronic graft-versus-host disease. Its technology centered on a subfractionation culturing method designed to derive single-cell clonal mesenchymal stem cell lines from bone marrow and support GMP manufacturing. Available evidence suggests the company is no longer active, with a Korean business registry indicating closure in 2014. Publicly visible pipeline information is limited and appears to center primarily on the Homeo-GH/cMSC program.